305790-76-5

Basic information

• Product Name: N-(5-Bromo-2-nitrophenyl)-L-proline
• Synonyms: N-(5-Bromo-2-nitrophenyl)-L-proline
• CAS NO: 305790-76-5
• Molecular Formula: C11H11BrN2O4
• Molecular Weight: 315.12
• Product Categories: pharmacetical
• Mol File: 305790-76-5.mol

Chemical Properties

• Boiling Point: 498.8°Cat760mmHg
• Flash Point: 255.4°C
• Appearance: /
• Density: 1.71g/cm³
• Vapor Pressure: 9.1E-11mmHg at 25°C
• Refractive Index: 1.645
• CAS DataBase Reference: N-(5-Bromo-2-nitrophenyl)-L-proline(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-Bromo-2-nitrophenyl)-L-proline(305790-76-5)
• EPA Substance Registry System: N-(5-Bromo-2-nitrophenyl)-L-proline(305790-76-5)

Safety Data

• Hazardous Substances Data: 305790-76-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H11BrN2O4/c12-7-3-4-8(14(17)18)10(6-7)13-5-1-2-9(13)11(15)16/h3-4,6,9H,1-2,5H2,(H,15,16)/t9-/m0/s1

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 147-85-3 L-proline 

Relevant articles and documents

Benzimidazolones and analogues

The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R5are independently selected from H or optionally substituted C1to C6alkyl, C2to C6alkenyl, C2to C6alknyl, C3to C8cycloalkyl, substituted C3to C8cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4and R5to from a 5 to 7 membered ring; R1is selected from H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, substituted alknyl, —COH, or optionally substituted —CO(C1to C3alkyl), —CO(aryl), —CO(C1to C3alkoxy), or —CO(C1to C3aminoalkyl) groups; R2is selected from H, halogen, CN, NO2, or optionally substituted C1to C6alkyl, C1to C6alkoxy, or C1to C6aminoalkyl groups; R3is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromatic ring containing 1 or 2 substituents; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt thereof. The invention also includes methods of contraception and methods of treating or preventing maladies associated with the progesterone receptor.

Combination therapies using benzimidazolones

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R6are independently selected from H or optionally substituted C1to C6alkyl, C2to C6alkenyl, C2to C6alkynyl, C3to C8cycloalkyl, substituted C3to C8cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4and R5to from a 5 to 7 membered ring; R1is selected from H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, substituted alkynyl, —COH, or optionally substituted —CO(C1to C3alkyl), —CO(aryl), —CO(C1to C3alkoxy), or —CO(C1to C3aminoalkyl) groups; R2is selected from H, halogen, CN, NO2, or optionally substituted C1to C6alkyl C1to C6alkoxy, or C1to C6aminoalkyl groups; R3is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromnatic ring containing 1 or 2 substituents; or a pharmaceutically acceptable salt thereof, in combination with a progestational agent, an estrogen, or both or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. These combinations may also be used to in methods of contraception, to stimulate food intake or for minimization of side effects or cyclic menstrual bleeding.